Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21933407 | 0.92 | TSHR (0.51) | TSHRALDH1A1TDP1THRB | |
| SCHEMBL11337160 | 0.82 | TSHR (0.57) | TSHRALDH1A1MAPK1TDP1THRB | |
| SCHEMBL28813009 | 0.81 | TSHR (0.55) | TSHRALDH1A1TDP1THRB | |
| Methacrylic Acid SCHEMBL176348 | 0.80 | TSHR (0.62) | TSHRALDH1A1MAPK1TDP1 | |
| SCHEMBL20723256 | 0.80 | TSHR (0.50) | TSHRALDH1A1MAPK1TDP1THRB | |
| SCHEMBL2148573 | 0.79 | TSHR (0.55) | TSHRALDH1A1MAPK1TDP1THRB | |
| SCHEMBL21776911 | 0.78 | TSHR (0.75) | TSHRALDH1A1MAPK1TDP1 | |
| SCHEMBL22686669 | 0.77 | THRB (0.64) | TSHRALDH1A1THRB | |
| SCHEMBL30094953 | 0.77 | TSHR (0.54) | TSHRALDH1A1MAPK1TDP1THRB | |
| SCHEMBL10477338 | 0.76 | TSHR (0.65) | TSHRALDH1A1MAPK1TDP1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1750127-B1 | Method of affinity separation. | SHISEIDO CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20110021756-A1 | METHOD OF MANUFACTURING AN AFFINITY PARTICLE, AFFINITY PARTICLE, AND SEPARATION METHOD | SHISEIDO COMPANY, LTD. (JP) | 2011-01-27 | — | — | US | disclosed |
| US-20090321358-A1 | Affinity Particle And Method Of Affinity Separation | SHISEIDO COMPANY, LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20070241054-A1 | Affinity Particle And Method Of Affinity Separation | SHISEIDO COMPANY, LTD. (JP) | 2007-10-18 | — | — | US | disclosed |
| EP-1750127-A1 | AFFINITY PARTICLE AND METHOD OF AFFINITY SEPARATION | Shiseido Company, Limited (JP) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021756-A1 | METHOD OF MANUFACTURING AN AFFINITY PARTICLE, AFFINITY PARTICLE, AND SEPARATION METHOD | FCGR1A, FCGR3B, FCGR2A | TSHR 332/4885ALDH1A1 849/4885MAPK1 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.